Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ProKidney Corp.
  6. Summary
    PROK   KYG7S53R1049

PROKIDNEY CORP.

(PROK)
  Report
End-of-day quote Nasdaq  -  2022-09-25
8.810 USD   -4.24%
09/23BofA Securities Starts ProKidney at Buy With $14 Price Target
MT
09/23ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
AQ
09/19ProKidney Corp.(NasdaqCM:PROK) added to S&P TMI Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
09/21/2022 09/22/2022 09/23/2022 09/26/2022 09/27/2022 Date
8.69 8.87 9.2 8.81 9.1 Last
104720 97765 59950 28962 13234 Volume
-10.69% +2.07% +3.72% -4.24% +3.29% Change
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -191 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,87x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -215 M - -
Net Debt 2023 - - -
P/E ratio 2023 -4,35x
Yield 2023 -
Capitalization 560 M 560 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 77
Free-Float 15,2%
More Financials
Company
ProKidney Corp., formerly Social Capital Suvretta Holdings Corp. III, is a clinical-stage biotechnology company. The Company is focused on developing a cell therapy platform capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. Its lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to stabilize or improve... 
Sector
Biotechnology & Medical Research
Calendar
09/29 | 01:30pmPresentation
More about the company
All news about PROKIDNEY CORP.
09/23BofA Securities Starts ProKidney at Buy With $14 Price Target
MT
09/23ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
AQ
09/19ProKidney Corp.(NasdaqCM:PROK) added to S&P TMI Index
CI
09/08Prokidney Corp. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/08ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
AQ
09/02Evercore ISI Initiates Coverage on ProKidney With Outperform Rating
MT
08/31ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor R..
AQ
08/31ProKidney Corp. Appoints Glenn Schulman as Senior Vice President of Investor Relations
CI
08/12Prokidney : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPE..
PU
08/12PROKIDNEY CORP. Completion of Acquisition or Disposition of Assets, Financial Statemen..
AQ
08/12Prokidney : Reports Second Quarter 2022 Financial Results and Provides Business Update - F..
PU
08/12Prokidney : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/12PROKIDNEY CORP. Management's Discussion and Analysis of Financial Condition and Result..
AQ
08/12ProKidney Posts Wider Q2 Loss
MT
08/11ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Upd..
AQ
More news
News in other languages on PROKIDNEY CORP.
08/31ProKidney Corp. nomme Glenn Schulman au poste de vice-président principal des relations..
08/12ProKidney affiche une perte plus importante au deuxième trimestre
08/11ProKidney Corp. annonce des nominations au conseil d'administration
07/20ProKidney Corp. nomme Kerry Cooper au poste de vice-président principal des affaires mé..
07/11ProKidney LLC a finalisé l'acquisition de Social Ca..
More news
Analyst Recommendations on PROKIDNEY CORP.
More recommendations
Chart PROKIDNEY CORP.
Duration : Period :
ProKidney Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 9,10 $
Average target price 14,00 $
Spread / Average Target 53,8%
EPS Revisions
Managers and Directors
Timothy A. Bertram Chief Executive Officer & Director
James Coulston Chief Financial Officer
Pablo Gerardo Legorreta Chairman
Ashley H. Johns Vice President-Clinical Operations
Libbie P. McKenzie Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PROKIDNEY CORP.-11.01%560
MODERNA, INC.-51.87%46 823
IQVIA HOLDINGS INC.-35.18%34 705
LONZA GROUP AG-42.20%32 942
SEAGEN INC.-12.45%24 949
ALNYLAM PHARMACEUTICALS, INC.16.40%23 692